(Q36781543)

16 August 2017

Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis (English)

1 reference

16 August 2017

metastatic breast cancer

1 reference

1

Joyce O'Shaughnessy

1 reference

16 August 2017

William J Gradishar

2

1 reference

16 August 2017

Paul Bhar

series ordinal

3

1 reference

16 August 2017

Jose Iglesias

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

6 April 2013

1 reference

Breast Cancer Research and Treatment

16 August 2017

1 reference

16 August 2017

138

1 reference

16 August 2017

3

1 reference

16 August 2017

829-837

1 reference

Creative Commons Attribution-NonCommercial 2.5 Generic

16 August 2017

start time

1 April 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

US Food and Drug Administration approval overview in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

The significance of the site of recurrence to subsequent breast cancer survival.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

Extending survival with chemotherapy in metastatic breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

Human breast cancer: survival from first metastasis. Breast Cancer Study Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

Prognostic factors for patients with liver metastases from breast cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631516

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10549-013-2447-8

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23563958

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23563958

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23563958

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10549-013-2447-8

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

23563958

1 reference